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Abstract: The great advances in the studies on metal complexes for the treatment of different cancer
forms, starting from the pioneering works on platinum derivatives, have fostered an increasingly
growing interest in their properties and biomedical applications. Among the various metal-containing
drugs investigated thus far, ruthenium(III) complexes have emerged for their selective cytotoxic
activity in vitro and promising anticancer properties in vivo, also leading to a few candidates in
advanced clinical trials. Aiming at addressing the solubility, stability and cellular uptake issues of low
molecular weight Ru(III)-based compounds, some research groups have proposed the development
of suitable drug delivery systems (e.g., taking advantage of nanoparticles, liposomes, etc.) able to
enhance their activity compared to the naked drugs. This review highlights the unique role of Ru(III)
complexes in the current panorama of anticancer agents, with particular emphasis on Ru-containing
nanoformulations based on the incorporation of the Ru(III) complexes into suitable nanocarriers in
order to enhance their bioavailability and pharmacokinetic properties. Preclinical evaluation of these
nanoaggregates is discussed with a special focus on the investigation of their mechanism of action at
a molecular level, highlighting their pharmacological potential in tumour disease models and value
for biomedical applications.
Keywords: Ruthenium(III) complexes; nanocarriers; nanoaggregates; drug delivery; anticancer
therapy; preclinical evaluation
1. Introduction
1.1. From Platinum(II) to Ruthenium(III)-based Complexes: The Importance of Nanoformulations in Metallo
Drug Delivery
The interest in metal-based complexes for the treatment of cancer started with the serendipitous
discovery of the anti-tumour properties of cis-diamminedichloroplatinum(II) (cDDP or cisplatin)
in the early 1960s [1,2]. Approved in 1978 by the Food and Drug Administration [3], cisplatin is
used in the treatment of a broad spectrum of human cancer malignancies either as single agent
(cervical, bladder, head, and neck cancer) or in combination treatments (testicular, bladder, head and
neck cancer) [4]. The cytotoxicity of cisplatin is due to its interaction with DNA, forming adducts
preferentially with adjacent guanines, thus interfering with replication and transcription processes
and ultimately triggering apoptosis, as main cell death pathway [5–8]. Unfortunately, dose-limiting
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side effects (nephrotoxicity, ototoxicity and peripheral neurotoxicity) and its intrinsic or acquired
resistance hindered its widespread use [4,9,10], stimulating the search for new, safer metal-based
anticancer agents.
Second- and also third-generation Pt(II) complexes have been developed over the last 50 years,
with about more than 20 Pt(II)-based compounds entered in clinical trials. Of these, only two
(carboplatin [11] and oxaliplatin [12]) obtained international marketing approval, respectively, in 1992
and 2002, and three others (nedaplatin, lobaplatin and heptaplatin) were approved only in individual
countries (Japan, China and Korea, respectively) [13–15].
Afterwards, novel anticancer agents based on metals different from platinum were developed,
as extensively reported in several review articles [16–23]. Among all the metal derivatives thus far
investigated, ruthenium complexes in the +2 and +3 oxidation states gained increasing attention as
valuable alternatives to Pt(II)-based ones [24–33].
However, clinical application of metallodrugs, when administered via conventional intravenous
methods, has been hampered by their limited aqueous solubility and short in vivo half-lives, resulting in
inadequate bioavailability and low accumulation in the tumour masses. Thus, several approaches have
been proposed to address these issues, particularly exploiting nanotechnology-based strategies [34–37].
The main advantages of using nanosystems for drug delivery include their high stability, notable
loading capacity and possibility to achieve controlled or sustained drug release. This approach can
significantly increase the circulation time in the body, limit the susceptibility to chemical and/or
enzymatic degradation, target specific tumour sites and reduce the toxic side effects associated with
drug administration [28,37–42].
As far as Ru(II)-based complexes are concerned, their preparation, encapsulation into different
nanosystems and studies on their mechanism of action have been comprehensively described in recent
overviews [43,44].
In this review we report the state-of-the-art on anticancer Ru(III)-based complexes including the
ad hoc designed nanoformulations to incorporate and deliver these antiproliferative agents. Particular
emphasis is given to the emerging strategies to facilitate the application of Ru(III)-based drugs in vivo,
aimed at enhancing their solubility and bioavailability, as well as improving their delivery to cancer
cells. In addition, the biological activity of these Ru(III)-containing nanosystems and, where known,
their mechanism of action is discussed, focusing on the contribution of our group in this field and the
most recent literature examples.
1.2. Anticancer Activity and Mechanism of Action of the Lead Low Molecular Weight Ru(III)-Based
Compounds
To the best of our knowledge, three Ru(III)-containing compounds entered in clinical trials:
NAMI-A [45,46], KP1019 [47–53], as well as its sodium salt analogue named IT-139, formerly known
as NKP-1339 [54–58]. Despite their structural similarities (Figure 1), these complexes dramatically
differ in their bioactivity [59]. In fact, preclinical studies demonstrated that NAMI-A was essentially
inactive against primary tumours but proved to specifically affect tumour metastases, preventing their
development and growth [45,46]. In contrast, KP1019 exhibited marked cytotoxic activity in vitro in
cisplatin-resistant human colon carcinoma cell lines, as well as significant anti-tumour effects in vivo
against a wide variety of tumour xenografts through induction of apoptosis [47–53]. NKP-1339 is the
most recent compound entered in clinical trials against solid cancer forms, showing a manageable
safety profile with absence of neurotoxicity and dose-limiting haematological toxicity [54–58].
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Analogously to its congeners, AziRu proved to bind both nucleic acids and proteins.[83–86] 
Detailed spectroscopic and mass spectrometric investigations showed AziRu to be more reactive 
towards DNA model systems—both single stranded and duplex oligonucleotides—than NAMI-
A.[85] Moreover, its capability to interact with model proteins—such as bovine pancreatic 
ribonuclease A (RNase A)[84] and hen egg white lysozyme (HEWL)[83]—was investigated by X-ray 
crystallography and Raman microscopy studies. In both model proteins, crystal structure analysis 
indicated that the protein conformation was not dramatically affected by Ru complexation and that 
the metal lost all its original ligands upon binding.[83,84] In particular, experiments with HEWL 
protein also underlined the ability of AziRu, upon aging, to form polyoxo species containing Ru-O-
Ru bond.[83,87] 
More recently, studies aimed at identifying AziRu release conditions from bound proteins were 
carried out, using a Raman-assisted crystallographic approach to investigate the AziRu/HEWL 
complex as a case study. Crystallography was used to identify the protein structural changes and 
metal release occurring upon RuIII → RuII reduction by alternative exposure to different reducing 
agents, while Raman microscopy on protein crystals allowed identifying the spectral changes 
attributable to the reduction of Ru(III) bound to the protein.[86] These studies clearly indicated a Ru 
reduction in the protein complex, followed by a Ru release mechanism dependent on the reducing 
agent: reduction with hydrazine produced a native-like lysozyme crystal with a Raman spectrum 
Figure 1. Chemical structures of NAMI-A, KP1019, NKP-1339 and AziRu. Here, ruthenium ions
are indicated in red, the counterions in green, while the N- and S-donor ligands in dark and light
blue, respectively.
Many preclinical studies have investigated the mechanism of action of these complexes. A large
body of evidence has been gathered proving that these Ru(III) complexes are able to interact with
plasma proteins—particularly with serum albumin [60–64] and transferrin [65–69]—and/or bind nucleic
acids [70–73]. The extensive binding to serum proteins for KP1019 and NAMI-A was also reflected by
their low distribution volume in clinical phase I evaluation [45,51].
As concerns the interaction with cancer cells, X-ray fluorescence imaging measurements revealed
a wide intracellular distribution of KP1019 both in cytosol and in the nuclear region after treatment;
conversely, following NAMI-A administration in vitro, ruthenium was not detected inside the cells,
suggesting its strong interaction with cell membranes as well as alternative mechanisms of action [74].
Stimulated by the positive impact of Ru(III) complexes in the panorama of known anticancer agents,
Walsby et al. [75,76] as well as our group [77] independently and almost simultaneously described
a NAMI-A-like complex carrying a pyridine residue in place of the imidazole ligand, and sodium
replacing imidazolium as the counterion (Figure 1, right). This novel compound, called NAMI-Pyr by
the first research group and AziRu by the second one, overall proved to be poorly cytotoxic, similarly
to the parent NAMI-A, however showing IC50 values half that of NAMI-A on human breast MCF-7
and cervical HeLa cancer cell lines (Table 1) [77–79].
The overall higher cytotoxicity observed for this pyridine-containing Ru complex vs. NAMI-A
was explained by the chemical properties of the nitrogen ligand, which compared to imidazole confers
higher lipophilicity and, thus, expectedly improved cellular uptake [75,80–82].
Analogously to its congeners, AziRu proved to bind both nucleic acids and proteins [83–86].
Detailed spectroscopic and mass spectrometric investigations showed AziRu to be more reactive
towards DNA model systems—both single stranded and duplex oligonucleotides—than NAMI-A [85].
Moreover, its capability to interact with model proteins—such as bovine pancreatic ribonuclease A
(RNase A) [84] and hen egg white lysozyme (HEWL) [83]—was investigated by X-ray crystallography
and Raman microscopy studies. In both model proteins, crystal structure analysis indicated that the
protein conformation was not dramatically affected by Ru complexation and that the metal lost all its
original ligands upon binding [83,84]. In particular, experiments with HEWL protein also underlined
the ability of AziRu, upon aging, to form polyoxo species containing Ru-O-Ru bond [83,87].
More recently, studies aimed at identifying AziRu release conditions from bound proteins were
carried out, using a Raman-assisted crystallographic approach to investigate the AziRu/HEWL complex
as a case study. Crystallography was used to identify the protein structural changes and metal
release occurring upon RuIII → RuII reduction by alternative exposure to different reducing agents,
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while Raman microscopy on protein crystals allowed identifying the spectral changes attributable to
the reduction of Ru(III) bound to the protein [86]. These studies clearly indicated a Ru reduction in the
protein complex, followed by a Ru release mechanism dependent on the reducing agent: reduction
with hydrazine produced a native-like lysozyme crystal with a Raman spectrum identical to the
wild-type protein, suggesting the complete Ru release from the protein upon reduction. In contrast,
the Raman analysis on AziRu/HEWL crystals treated with ascorbate suggested that in this case the
RuIII → RuII reduction occurred without Ru release. The observed differences in the hydrazine-
and ascorbate-induced action indicated a two-step Ru reduction-release mechanism [86]. To better
understand this process, a pH-dependent, spectroelectrochemical surface-enhanced Raman scattering
(SERS) study was also performed on AziRu-functionalized Au electrodes as a surrogate and simple
model system mimicking the anticancer Ru(III)-based drugs. This SERS study allowed determining
a pKa of 6.0 ± 0.4 for the aquated AziRu complex in the RuIII state, which corresponds to the pH
values characteristic of the external microenvironment of most cancer cells, significantly differing from
healthy ones. These experiments also indicated a dramatic shift of the redox potential (E0) by > 600
mV for the aquated AziRu species toward more positive potentials upon acidification, suggesting a
selective AziRu reduction in cancer environments but not in normal ones [86].
1.3. Nucleolipid and Aminoacyl Lipid-based Structures Incorporating AziRu, a NAMI-A-Like Ruthenium
Compound
All the described ruthenium complexes proved to be poorly stable in aqueous media, where the
most labile ligands, typically chloride ions, are easily and relatively rapidly replaced by hydroxide
ions and/or water molecules, resulting in hydrolysis of the complexes [85,88–95], also leading to
poly-oxo species formation [83,89,96,97]. Although it has been reported, at least for NAMI-A, that the
presence of these oligomeric species does not really impair the overall anti-tumour activity [89,98],
the premature formation of aquated species in the extracellular medium could deactivate, or activate
too early, most of the administered drug, thus reducing the available active forms which ultimately
interact with the biological targets (proteins or DNA) [3,99]. For this reason, the effective biomedical
potential of these low molecular weight ruthenium complexes, administered as such, has been recently
reconsidered. Taking into account that the ligand exchange process could also represent a potential
mechanism of action of the Ru(III)-based drugs, or of activation in case they behave as prodrugs of the
more reactive Ru(II)congeners, several efforts have been made to retard the ligand exchange processes
in the extracellular environment so to ensure their occurrence once the drug has reached the cell.
Following the investigations carried out on KP1019 and NAMI-A [72], in a recent study the
subcellular accumulation of AziRu was determined by inductively coupled plasma-mass spectrometry
(ICP-MS) analysis performed on various biological samples taken from MCF-7 breast cancer cell
cultures (culture medium, cellular pellet, cytosolic fraction, nuclear fraction and DNA samples) after
24 h of in vitro ruthenium treatment [100]. About 80% of the administered ruthenium was found
in the culture medium, while only a very small amount (less than 10%) was detected in the nuclear
fraction [100]. This result corroborated the hypothesis of a massive early drug deactivation in the
extracellular environment and/or a poor ability to penetrate the cell membranes, reinforcing the need
to protect the metal core in Ru-based drugs in order to obtain more efficient cell internalization.
Thus, in order to produce more effective Ru(III)-based anticancer agents, able to cross the
biological barriers, our research group proposed a prodrug approach. In this design, the active
unit, AziRu, has been incorporated into highly functionalized nucleolipid-based scaffolds [101] able
to form, under physiological conditions, stable self-assembling aggregates efficiently protecting
the metal complex from biological degradation and conveying it through the cell phospholipidic
bilayers [77,79,102–109].
In detail, the low molecular weight complex AziRu was decorated using ribo- and
deoxyribonucleosides as starting building blocks, functionalized with suitable hydrophilic
(oligoethylene glycol moieties) and lipophilic (oleoyl or cholesteroxyacetyl groups) chains,
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obtaining a mini-library of amphiphilic nanovectors to enhance the Ru(III) delivery in vivo.
Within this approach, the nucleolipid-based Ru(III) complexes—named ToThyRu, HoThyRu,
DoHuRu [77,106], ToThyCholRu [79,105], the fluorescently-labelled HoThyDansRu [100,106] and
the second-generation HoUrRu [107] (Figure 2)—were successfully prepared and evaluated in their
physico-chemical properties (for a recent review covering their design, synthesis and characterization,
see Riccardi et al. [35]).
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In order to further expand the chemical diversity of the available amphiphilic Ru(III) complexes,
a central core alternative to the nucleolipidic one, i.e., the trifunctional α-amino acid glutamic acid,
was explored to build the nanocarrier for the Ru(III) metal core [110]. The novel aminoacyl lipidic
Ru(III) complex I (Figure 2) showed a slower hydrolysis kinetics compared to AziRu, demonstrating
that also an aminoacyl lipid is a suitable scaffold to protect the Ru(III) complex from the aquation
processes [110].
2. Ru(III)-Containing Formulations as Efficient Drug Delivery Systems
2.1. KP1019-Hosting Nano ystems
In order to overcome the poor stability observed for KP1019 in aqueous solutions, especially at
physiological pH, Keppler et al. proposed an interesting approach [111]. KP1019 was entrapped in
poly(lactic acid) nanoparticles (PLA NPs) in the presence of two different non-ionic surfactants: the
poloxamer Pluronic F-68 and polysorbate Tween 80 (Figure 3a), in order to evaluate the contribution of
the surfactant on the chemical stability and encapsulation properties of the final nanoaggregates [111].
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These formulations, prepared by a single oil-in-water (o/w) emulsion and characterized by dynamic
light scattering (DLS) and transmission electron microscopy (TEM) analyses, were essentially based on
physical encapsulation, which exploits the affinity between the carrier and the drug to entrap the latter
one in a suitable matrix.
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exchange reaction was also accompanied by reduction of the paramagnetic Ru(III) to the diamagnetic 
Ru(II) ion, as revealed by electron spin resonance (ESR) spectra, and explained by the well-known 
autoxidation ability of polysorbates.[111] 
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polylacti acid and of the surfactant used in the formulation (poloxamer Pluronic F-68 a d polysorbate
Tween 80); (b) na oparticle ppearanc fter differ nt mperature and period storage: TWNP_3 (5 d,
4 ◦C), TWNP_2 (24 h, 4 ◦C), TWNP_4 (24 h, 25 ◦C), TWNP_1 (2 h, 25 ◦C), blank TWNP, from left to
right; (c) IC50 values (µM) of th different KP1019 nanoformulatio s prepared in comparison with
naked KP1019. Blank TWNP_ (1 month, 4 ◦C), Blank TWNP_2 (2 h, 25 ◦C); IC50 values are reported as
mean ± SEM. (d) ose-response curves of c lon carci oma SW480 and the hepat Hep3B c cer c ll
lines with the indicated drugs as determin d by MTT assay after 72 h treatment. Figure were adapted
fro [111] publi hed by The Royal Society of Chemistr .
The Ru-containing nanoaggregates based on Pluronic F-68 (indicated as PLNP) clearly showed a
brown drug precipitation after ca. 15 h, suggesting that KP1019 diffused out of the PLNP and therefore
this kind of nanoformulation was not further explored [111].
On the contrary, the use of Tween 80 allowed preventing drug precipitation with very high KP1019
loading efficiency, ranging from 92% to 95% with respect to the initial amount. When stored at 4 ◦C,
the obtained formulations (indicated as TWNP) did not show settling of particles, indicating a substantial
stability without agglomerate formation for about 1 month. In turn, these polysorbate-containing NPs,
when left at r.t., showed a remarkable colour change from brown to deep green after ca. seven days,
indicative of the reduction of the Ru(III) centre (Figure 3b) [111].
This hypothesis was then investigated by kinetic studies: ESI-MS experiments demonstrated
the replacement of a chloride ligand by Tween 80, involving its moderately basic oxygen groups.
This exchange reaction was also accompanied by reduction of the paramagnetic Ru(III) to the
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diamagnetic Ru(II) ion, as revealed by electron spin resonance (ESR) spectra, and explained by the
well-known autoxidation ability of polysorbates [111].
The evaluation of the in vitro anticancer properties performed on colon carcinoma SW480 and
hepatoma Hep3B cell lines indicated a modest increase of the antiproliferative activity for the stable
NPs (stored at 4 ◦C), along with a markedly higher cytotoxic activity for the NPs left at r.t. (Figure 3c,d).
Indeed, green NP solutions showed a 20- and 26-fold increased cytotoxic activity with respect to the
naked KP1019 drug, respectively on SW480 and Hep3B cancer cells. Thus, surprisingly, longer storage
period distinctly increased the activity of the KP1019-loaded TWNP particles [111].
For KP1019, the same research group also proposed a strategy alternative to the physical
encapsulation, based on the chemical conjugation of the ruthenium complex with a selected
polymer [112]. In particular, KP1019 was loaded into micelle-like carriers (MC-KP1019) formed
by an ad hoc synthesized PEGylated polymer. Indeed, micelles proved to be highly biocompatible
and efficient [113,114]. The obtained micelles were fully characterized by TEM and zeta potential
measurements in order to determine their size range and surface charge. In addition, MC-KP1019
solutions (0.3 mg/mL KP1019) proved to be stable at 4 ◦C, with no precipitation for more than three
months [112].
Then, the anticancer activity of MC-KP1019 was evaluated following 72 h drug incubation
and compared with naked KP1019 on different human cancer cell lines, i.e., the colon carcinoma
cell line HCT116 and its subline HCT116 (p53/ko) with a deleted p53 gene, the non-small
cell lung carcinoma cell line SW1573 with its ABCC1- and LRP-overexpressing subline 2R120,
and its ABCB1- and ABCC1-overexpressing subline 2R160, the epidermal carcinoma cell line
KB-3-1 and its ABCB1-overexpressing subline KBC-1, the breast cancer cell model MCF-7 and
its ABCB1-overexpressing subline MCF-7/adr, along with the human colon adenocarcinoma Lovo and
its ABCB1- overexpressing subline Lovo/dox. In all cases, KP1019-containing micelles were found to
be more active than naked KP1019, showing IC50 values between 1.6- and 22.7-fold lower compared to
the free Ru compound (IC50 values ∼100 µM or above) [112].
Notably, in the SW1573 sublines 2R160 and 2R120, both being distinctly resistant to KP1019,
the micellar formulation of KP1019 was able to overcome this resistance, showing very interesting
cytotoxicity [112]. Moreover, the micelle-based nanosystems facilitated the cellular accumulation of
KP1019, as determined by ICP-MS measurements. Concerning their mode of action, increased cell cycle
arrest in G2/M phase (PI-staining), DNA damage (Comet assay) as well as enhanced levels of apoptotic
cell death (caspase 7 and PARP cleavage) were found in HCT116 cells treated with the MC-KP1019
nanoformulations [112].
2.2. NAMI-A-Hosting Nanosystems
The micellization approach has been explored to enhance also the in vivo delivery of NAMI-A.
Stenzel and coworkers reported the polymerization of 4-vinil imidazole (VIm) using a
trithiocarbonate RAFT agent, i.e., 2-[(dodecylthio-carbonothioyl)thio]-2-methylpropanoic acid, and the
subsequent chain extension with poly(ethylene glycol)methyl ether acrylate (PPEGMEA) to obtain
a biocompatible amphiphilic block copolymer capable to self-assemble into polymeric micelles and
incorporate NAMI-A (indicated as P(NAMI-A)-PPEGMEA, Figure 4a) [115].
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4. NAMI-A conjugation to polymeric micelles: (a) chemical structure of the amphiphilic
block copolymer P(NAMI-A)-PPEGMEA and schematic r prese tation of its micellization in water;
(b) cytotoxicity and IC50 values (µM, expressed in terms of ruthenium concentration) of I-
I- )- a ai st ovarian 2780 and vcar-3 and a creatic s -1 cancer ce l lines.
50 values are reporte as ea SEM. Figures were adapted ith per issi fr [ ]
.
The polymerization reaction was followed by SEC analysis monitoring the retention time changes
due to the increased polymer size over time and the resulting micelles were then characterized by DLS
and TEM experiments (Figure 4a) [115].
When tested on ovarian (A2780 and Ovcar-3) a d highly aggressive pa creatic AsPC-1 cancer
cell lines, a 1.5-times increase in cytotoxicity was found in all the tested cell lines for the polymeric
NAMI-A-containing micelles compared to the naked ruthe ium complex (Figure 4b) [115].
Notably, polymeric micelles significantly improved also the NAMI-A antimetastatic potential,
with increased inhibitory effects on both the migration and invasion of human breast cancer cells [115].
In particular, the influence of the polymeric P(NAMI-A)-PPEGMEA micelles on the migration
processes of three cell lines (invasive cancerous MDA-MB-231, noninvasive cancerous MCF-7 cancerous
noncancerous CHO) was evaluated when a chemical (chemotaxis) and a contact (haptotaxis) stimulus
was applied to promote cell movements. Both the chemotactic and haptotactic migration of breast
cancer cells were inhibited in a massive way with respect to the nontumourigenic CHO cells, with
statistically significant effects observed for the invasive MDA-MB-231 cell line [115].
2.3. AziRu-Hosting Nanosystems
Recently, Tesauro and colleagues proposed a variant of the well-known AziRu (indicated in
this work as RuPy by the authors) containing a fully protected sugar moiety as decoration for
the ruthenium-coordinating pyridine moiety (named RuPyTry, Figure 5a) aiming at increasing the
Ru(III)complex cell internalization [116]. This novel complex, fully characterized by ESI-MS, IR and 1H
NMR spectroscopy, showed a faster hydrolysis in aqueous solution with respect to its parent compound,
with formation of the respective monoaqua complex, probably favoured by the hydrogen-bonding
properties of the nitrogen atoms in the triazole moiety facilitating the access of water molecules to the
metal [116].
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Figure 5. Pyridine-containing Ru(III) complexes inserted in liposome systems: (a) chemical structure of
the proposed RuPy and RuPyTry compounds; (b) schematic representation of liposomal nanoaggregates
containing the pyridine-based Ru(III) complexes; (c) dose-response histograms reporting the cytotoxic
effects observed for the naked Ru(III) compounds and their liposomal formulations in PC-3 cancer cells
after 48 h treatment. Figures are adapted from [116].
Then, Ru-co taining liposome formulations were prepared mixing phosphatidylcholine
(PC)/cholesterol (Chol)/DSPEPeg2000 in 57/38/5 molar ratio (Figure 5b). The obtained liposomes,
with ca. 100 nm size, exhibited very slow ruthenium release kinetics, with only 4% of the complex
released in serum over 72 h monitoring [116].
These Ru(III) complexes as such, as well as their liposomal nanoaggregates, LipoRuPy and
LipoRuPyTry, were evaluated for their anticancer activity analysing the inhibition of cell proliferation
on human prostate cancer PC-3 cells and human dermal fibroblasts (NHDF).
The naked Ru(III) complexes did not show significant cytotoxic effects on cancer PC-3 cells even
when tested at 100 µM concentration (Figure 5c); a slight decrease in cell viability was found only at
concentrations >500 µM. Conversely, the liposomal formulations exhibited relevant cytotoxicity under
the same conditions. The observed reduction in cell viability was found to be concentration-dependent
and more marked for the RuPy-containing liposomes (LipoRuPy, Figure 5c). In turn, when tested
on normal NHDF cells, these formulations did not affect cell viability even at 100 µM concentration,
demonstrating their selectivity and promising bioactivity [116].
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2.4. Mononuclear and Dinuclear Ru(III)-Dithiocarbamato Complexes Encapsulated in Nanosized Carriers
Fregona et al. [117] proposed novel mono- and dinuclear Ru(III)-complexes with aromatic and
non-aromatic dithiocarbamates as ligands: in particular, carbazolyldithiocarbamato derivatives (CDT)
and pyrrolidinedithiocarbamate (PDT) analogues were prepared (Figure 6a). These compounds were
fully characterized by physico-chemical techniques such as elemental analysis, ESI-MS spectrometry,
1H NMR UV–VIS and FT-IR spectroscopic studies [117].
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In order to address the solubility iss es typically associated with ruthe ium drugs under
physiological conditions, both CDT and PDT Ru(III)-based derivatives were encapsulated in
water-soluble micellar carriers by using the biocompatible copolymer Pluronic® F127 [117].
Such block copolymer is a non-ionic s rfactant consisting of hydrophilic poly(ethylene oxide)
(PEO) and hydrophobic poly(propylene oxide) (PPO), arranged in A-B-A tri-block structure which
comprise a hydrophobic PPO region covered by a hydrophilic shell, m de up of PEO chains [118].
The incorporati of the selected Ru(III)-based compounds during the micellization process was
driven by the hydrophobic interactions established between the compounds and the PPO domain
of the selected copolymer, he ce preventing unwanted release of the loaded compounds (Figure 6b
for the schematic representation of the micelle formation) [117]. As verified by UV–VIS analysis in
saline solution (NaCl 0.9% w/v), the prepared Ru(III)-incorporating micellar nanocarriers did not show
significant changes in the UV spectra over time, at least over 72 h monitoring [117].
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Both naked CDT- or PDT-based ruthenium compounds as well as their nanoformulations were
then tested in preliminary bioactivity assays on two human tumour epithelial cell lines, i.e., HeLa
(cervix adenocarcinoma) and HCT 116 (colon carcinoma) over 72 h treatment, using cisplatin as the
control [117].
Interestingly, the β form of the PDT dinuclear complex ([Ru2(PDT)5]Cl) evidenced a ca.
two-fold higher activity when loaded into Pluronic® F-127 micelles compared to its naked form.
This occurred also for the mononuclear PDT complex, showing a three-fold increased anticancer
activity (Figure 6c) [117]. Notably, all the PDT-based compounds proved to be more efficient against
cervical HeLa than on colon carcinoma HCT116 cancer cell lines, as also found for the Ru(III)-containing
nanosystems [109]. Conversely, both mononuclear and dinuclear Ru(III)-CDT complexes encapsulated
in Pluronic® F127 micelles were not active on the tested cell lines [117].
2.5. Liposome-Based Systems Containing Nucleolipid or Aminoacyl Lipid-Based Ru(III) Complexes
As in the case of low molecular weight Ru(III) compounds, also the nucleolipid- or aminoacyl
lipid-based complexes incorporating AziRu, here described in paragraph 1.3, when dissolved in
aqueous solutions, showed tendency to hydrolyse over time, even if sensibly reduced compared
to naked AziRu [77,105,110]. In order to further increase their stability and obtain liposome-based
delivery systems incorporating specific amounts of the selected Ru(III) complex, our group studied
the co-aggregation of both nucleolipid- and aminoacyl lipid-based Ru(III) complexes with either the
zwitterionic phospholipid POPC (1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine) or the cationic
lipid DOTAP (1,2-dioleoyl-3-trimethylammoniumpropane). A schematic representation of the obtained
liposome-based nanosystems is reported in Figure 7.
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Figure 7. Schematic representation of liposomal POPC- or DOTAP-based nanoaggregates containing
nucleolipid- or aminoacyl lipid-based Ru(III) complexes.
Liposomes, discovered in the 1960s, consist in phospholipid-based nanovesicles having a
morphology very similar to cellular membranes, with an aqueous core surrounded by lipid
bilayers [119–121]. Thanks to their peculiar structure, liposomes are considered ideal nanosystems to
encapsulate both hydrophilic and lipophilic drugs, respectively in the aqueous core and within the lipid
bilayer [122–124]. To date, liposomes also represent the most successful drug delivery systems [125],
with several formulations approved by FDA for anticancer therapy and also available in clinical
use [119,126–129], such as lipoplatin, a liposomal cisplatin formulation approved by FDA for pancreatic
and lung cancer treatment [130].
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Thus, POPC and DOTAP lipids were chosen as Ru(III) complexes stabilizing agents on the basis
of their proved biocompatibility [77,105,106,131,132]. In particular, POPC liposomes are efficiently
used in a broad range of biotechnological applications [133], while liposomes formed by the cationic
lipid DOTAP showed noteworthy transfection efficiency both in vitro and in vivo [131], probably due
to the favourable interactions with the negatively charged membranes.
The use of phospholipids—forming ordered bilayers in which the Ru complexes can be easily
lodged—allowed obtaining Ru(III)-containing formulations stable for months in physiological media,
in which the incorporated metal amount can be finely modulated.
On the other hand, the selected lipids allowed exploiting different interactions for the Ru-complex
embedding (mostly hydrophobic for POPC, and both hydrophobic and electrostatic for DOTAP),
thus providing a basis to evaluate a structure-activity rationale.
Generally, the Ru(III)-containing POPC formulations were prepared mixing the Ru complex
and the lipid in 15:85 molar ratio [77,105,107]. In turn, liposomes based on cationic DOTAP
lipid were able to incorporate a higher amount of the nucleolipid- or aminoacyl lipid-based Ru
complex, providing stable DOTAP co-aggregates with up to 30% in moles of ToThyCholRu [79]
or the aminoacyl lipid compound I [110], and 50% in moles of ToThyRu, HoThyRu, DoHuRu or
HoUrRu [106,107]. Both Ru(III)-containing liposomes showed effectively retarded ligand exchange
processes in physiological solutions [105,110].
On these Ru(III)-containing liposomes detailed preclinical studies were then carried out in order
to assess their anticancer activity and disclose their mechanism of action, so to evaluate their potential
in cancer treatments.
3. Antiproliferative Effects of Liposome-Based Systems Containing Nucleolipid or Aminoacyl
Lipid-Based Ru(III) Complexes: Insight into Their Mode of Action
3.1. In Vitro Bioactivity
In order to verify the antiproliferative efficacy of the nucleolipid- or aminoacyl lipid-based Ru(III)
complexes inserted in POPC- and DOTAP-based formulations, detailed investigations on their in vitro
bioactivity were performed in comparison with naked AziRu [77,79,100,105–107,110,134]. A selected
panel of human and non-human cancer cell lines was chosen, particularly focusing on cells of different
histopathological origin and widely used in anticancer research due to their replicative potential
and malignancy, such as MCF-7 (human breast adenocarcinoma cell line), WiDr (human epithelial
colorectal adenocarcinoma cell line), HeLa (human cervical cancer cells) and C6 (tumour rat glioma
cells) [134–136]. In parallel experiments, some of these formulations were also tested on normal cell
lines, such as L6 (rat muscle cells) and HaCaT (human keratinocytes cells), representing useful models
to assess possible biological effect on healthy cells [137]. The experimental procedures here adopted
involved the estimation of the anticancer activity by means of a “cell survival index”, arising from the
combination of a mitochondrial functional assay in vitro for the evaluation of the metabolic activity with
an automated cell count. From the resulting concentration/effect curves, IC50 values were determined
(Table 1).
In line with our expectations, liposomes exclusively composed by POPC or DOTAP did not interfere
with cell viability and proliferation [77,105,106]. On the contrary, all the tested Ru(III)-containing POPC-
and DOTAP-based formulations inhibited cancer cell proliferation at least one order of magnitude
more effectively than naked AziRu, with IC50 values in the low µM range, indicative of a significant
activity in reducing cancer cells growth (Table 1) [35,77,79,100,105–107,110,134].
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Table 1. IC50 values (µM) relative to AziRu and to the effective ruthenium concentration inserted in the
Ru(III)-incorporating POPC- and DOTAP-based liposomes in the indicated cell lines following 48 or 72
h of incubation in vitro. IC50 values are reported as mean ± SEM.
IC50 (µM)
MCF-7 WiDr C6 HeLa L6 HaCaT
NAMI-A [78] 620 ± 30 - - 626 ± 45 - -
AziRu [77,79] 305 ± 16 [77] 441 ± 20 [77] 318 ± 12 [77] 382 ± 19 [79] > 500 [79] > 500 [79]
POPC-based formulations
ToThyRu/POPC [77,134] 27.8 ± 0.1 [134] 75 ± 4 [77] 36 ± 8 [77] - - -
HoThyRu/POPC [77] 7 ± 4 40 ± 5 81 ± 7 - - -
DoHuRu/POPC [77,134] 18.9 ± 0.1 [134] 99 ± 5 [77] 24 ± 5 [77] - - -
ToThyCholRu/POPC [79,105] 70 ± 12 [105] 165 ± 10 [105] - - >500 [79] >500 [79]
HoUrRu/POPC [107] 14 ± 7 20 ± 8 - - - -
DOTAP-based formulations
ToThyRu/DOTAP [106,134] 10.1 ± 0.1 [134] 50 ± 11 [106] 54 ± 8 [106] - - -
HoThyRu/DOTAP [100,106] 13 ± 4 [100] 65 ± 8 [106] 43 ± 11 [106] - - -
DoHuRu/DOTAP [106,134] 10.3 ± 0.2 [134] 41 ± 10 [106] 34 ± 9 [106] - - -
ToThyCholRu/DOTAP [79] 13 ± 2 23 ± 8 - 34 ± 4 187 ± 1 377 ± 3
HoUrRu/DOTAP [107] 8 ± 5 12 ± 5 - - - -
I/DOTAP [110] 31.2 ± 2.7 - 35.4 ± 2.7 45.6 ± 3 - >150
Thus, the insertion of AziRu into highly functionalized scaffolds (nucleolipid or aminoacyl lipid
structures), along with the subsequent liposome encapsulation, allowed us converting a very weakly
cytotoxic compound into effective antiproliferative agents, with IC50 values from ∼4 to ∼50 times lower
than the parent metal complex [35,77,79,100,105–107,110,134].
The higher anticancer activity observed for the tested formulations with respect to the naked
AziRu suggested an enhanced cellular uptake efficiency for the Ru(III)-incorporating liposomes due
to nanovectorization [35,77,79,100,105–107,110,134]. Interestingly, when tested on healthy cell lines,
as human HaCaT keratinocytes and rat L6 muscle cells, the Ru(III)-containing liposomal formulations
did not show toxicity even at very high concentrations, demonstrating a selective cytotoxicity against
highly proliferative malignant cells (Table 1).
These in vitro outcomes placed these Ru(III)-containing liposomal formulations
among the most promising Ru-based anticancer agents currently described in the
literature [35,77,79,100,105–107,110,134], with only few reported cases showing similar in vitro
antiproliferative activity [80,111,116,117,138–141].
Furthermore, in most investigated cancer cells, the IC50 values for the DOTAP formulations
were significantly lower than those calculated for the same Ru(III) complex lodged in POPC
liposomes [35,79,100,106,107,134]. This indicates that, under identical experimental conditions, the
cationic DOTAP liposomes greatly enhanced the anticancer activity of the nucleolipidic Ru(III)
complexes, likely due to the positive net superficial charge of the nanocarriers which can promote the
interaction with cell membranes and, consequently, the drug internalization.
Interestingly, the differences among the various nucleolipidic Ru(III) complexes incorporated in
the liposomal formulations were not very significant, consistently with the rationale that the metal
centre is the effectively bioactive species and the different nucleolipids simply represent useful variants
of the carrier molecules [35].
From these bioscreens, MCF-7 breast cancer cells proved to be the most sensitive to ruthenium
treatments in vitro: for this reason, the evaluation of the cellular response to the exposure to some of
the developed Ru(III)-containing formulations was extended to other in vitro models of human breast
cancer cells (BCC), worldwide the most common invasive cancers in women [142–144]. In particular,
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ToThyRu and DoHuRu-containing liposomes (both POPC and DOTAP formulations) [134] as well as
HoThyRu/DOTAP formulations [100] were further investigated focusing on well-established breast
cancer cell lines: in addition to the epithelial-like breast adenocarcinoma MCF-7 cells, MDA-MB-231,
MDA-MB-436, MDA-MB-468 and CG5 cells were inserted into a panel of human breast cancer models
for preclinical evaluations (Table 2). The endocrine-responsive (ER) breast adenocarcinoma MCF-7 and
the triple-negative breast adenocarcinoma (TNBC) MDA-MB-231 cell models account for the great
majority of investigations on breast cancer cells and are considered the most reliable in vitro models of
breast cancer together with their variants CG5, MDA-MB-436 and MDA-MB-468, respectively [145–147].
Table 2. IC50 values (µM) relative to cisplatin (cDDP), AziRu and the effective ruthenium concentration
inserted in the Ru(III)-incorporating POPC- and DOTAP-based liposomes in the indicated BCC lines
following 48 h of incubation in vitro. IC50 values are reported as mean ± SEM.
IC50 (µM)
MCF-7 MDA-MB-231 MDA-MB-436 MDA-MB-468 CG-5 MCF 10A
cDDP [100,134] 17 ± 5 [100] –19 ± 4 [100] - 24 ± 1 [134] - -
AziRu [100,134] >250 >250 >250 >250 >250 >250
POPC-based formulations
ToThyRu/POPC [134] 27.8 ± 0.1 36 ± 3 >37.5 15.7 ± 0.1 19.4 ± 0.2 -
DoHuRu/POPC [134] 18.9 ± 0.1 15 ± 1 37 ± 1 20.4 ± 0.8 30.6 ± 0.8 -
DOTAP-based formulations
ToThyRu/DOTAP [134] 10.1 ± 0.1 10.8 ± 0.2 15.0 ± 0.2 14.7 ± 0.1 4.1 ± 0.2 -
DoHuRu/DOTAP [134] 10.3 ± 0.2 12.1 ± 0.3 20.0 ± 0.2 14.2 ± 0.1 3.3 ± 0.2 -
HoThyRu/DOTAP [100] 13 ± 4 12 ± 3 - - - >100
According to the reported IC50 values (Table 2), all the liposome formulations were effective in
reducing cell growth and proliferation, proving the high sensitivity of BCC to the action of Ru(III)-based
nanoaggregates, mainly of DOTAP-based formulations [134]. Notably, HoThyRu/DOTAP was basically
inactive when tested on MCF-10A cells (IC50 higher than 100 µM considering the effective ruthenium
concentration), used as a reliable model for normal human mammary epithelial cells. Taken together,
these outcomes proved a significant selectivity of these Ru(III)-hosting nanosystems towards BCC
lines, without significant biological effects on healthy counterparts of mammary gland as epithelial
cells [100,134].
3.2. Cellular Uptake Studies on Ru(III)-Containing Liposomes by Fluorescence Microscopy
In vitro preliminary investigations demonstrated that all the Ru(III)-containing liposomes were
endowed with significant antiproliferative activity toward cancer cells of different histological origin,
with particular efficacy on in vitro models of breast cancer cells.
Since one possible mechanism of action of the ruthenium-based anticancer drugs was suggested to
be the nuclear DNA binding [148,149], the cellular uptake and nuclear entry ability were investigated,
being a key element to induce inhibition of cancer cell proliferation [72].
Thus, time-course fluorescence microscopy experiments were performed to evaluate the
Ru(III)-containing liposome uptake and their subcellular localization in carcinoma cells at different
incubation times. In particular, ToThyRu/POPC formulations as well as DOTAP-based liposomes
containing either DoHuRu or ToThyCholRu were evaluated in parallel experiments as representatives
respectively of POPC and DOTAP-based nanoaggregates [77,79,106]. In the case of the cellular uptake
evaluation of ToThyRu/POPC and DoHuRu/DOTAP nanoformulations, breast MCF-7 cancer cells were
selected. In turn, the in vitro uptake of ToThyCholRu/DOTAP nanosystems was evaluated on both
MCF-7 and colorectal WiDr cancer cell lines, in order to verify possible differences toward cancer cells
of different histological origin.
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In these experiments, the liposomes were loaded also with the fluorescent rhodamine-B (Rhod)
dye, allowing to reveal their fusion with the membranes and cellular uptake; the blue fluorescent stain
DAPI was used to label DNA, in order to detect the position of the nuclei; finally, merged images,
arising from overlapped fluorophore emissions of DAPI and Rhod from the same cell monolayers,
gave a clear and unambiguous indication on the overall cellular uptake process and its kinetics.
For all the investigated formulations, independently from the analysed cancer cell line, a marked
fluorescence was detected into cells already after 1 h incubation. After typically 3 and 6 h, fluorescence
localized widespread in the nuclei, cytoplasm and close to the membranes, indicating that the liposomes
were significantly taken up by cancer cells [77,79,106]. Few differences in the cell uptake were found
on varying the lipid used in the formulation: indeed, in the case of DOTAP nanoaggregates hosting
DoHuRu or ToThyCholRu complexes, a massive cell uptake was already observed after 30 min
incubation [77,79,106]. Therefore, in all cases these formulations showed a high propensity to cross the
cell membranes along the uptake process in the tested cancer cell lines [77,79,106].
Aiming at a deeper insight into the cell internalization process and metabolic fate of the
liposomal formulations, additional in vitro fluorescence experiments were performed on MCF-7
cancer cells treated with an ad hoc prepared dansyl-labelled ruthenium complex named HoThyDansRu
(Figure 2), co-aggregated with DOTAP analogously to the other described nucleolipid-based complexes.
Monitoring the dansyl fluorescence, the fate of the active ruthenium complex could be directly assessed,
examining its localization after cells treatment. Cationic liposomes hosting the fluorescently labelled
HoThyDansRu rapidly localized within the cells, showing relevant cytoplasm dansyl-dependent
fluorescence emission already after 30 min incubation and increasing accumulation over time, reaching
the maximum fluorescence emission after 2 h (Figure 8a) [106]. A marked tendency to accumulate in
proximity of the nuclei was detected (Figure 8a), suggesting possible interaction of the active metal
also with nucleic acids [106].
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Overall, analysis of the dansyl-dependent fluorescence emission over time indicated that the
HoThyDansRu/DOTAP nanoaggregates first localized within the cell membranes, then entered
the cytoplasm, spreading to the whole cell, including perinuclear and nuclear compartments
(Figure 8b) [100].
The fluorescence detection suggested an intracellular release of the ruthenium derivative from the
liposomes: at longer incubation times (i.e., 4 and 6 h), a significant decrease in the dansyl-dependent
fluorescence signal intensity occurred (Figure 8b), supporting the hypothesis that the liposome released
the active ruthenium complex inside the cell [100]. In fact, it was demonstrated that the fluorescence
intensity of the dansyl probe is largely influenced by the external environment: the fluorescence of
dansyl group is marked in hydrophobic environments, while poor fluorescence emission is detected
when the probe is exposed to water [150–152]. Accordingly, the marked fluorescence intensity of
HoThyDansRu in the first monitoring indicated that the dansyl dye was inserted in the apolar
DOTAP lipid bilayer; its progressively less and less intense fluorescence (Figure 8b) suggested that the
nucleolipid Ru-complex was released in the intracellular media [100].
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All these findings were thus corroborated in MCF-7 cells by fluorescence experiments using
confocal microscopy coupled to Red E-cadherine-associated fluorophore, a 120-kDa transmembrane
glycoprotein able to highlight adherens junctions and cell-cell contacts in epithelial clusters [100].
Overall, these data highlighted the crucial role played by the cellular uptake process in determining
the anticancer efficacy of Ru(III)-based drugs, showing both POPC and DOTAP-based liposomes as
very efficient nanocarriers for the stabilization of Ru complexes in aqueous media and their effective
transport in cells. Particularly relevant was their clear detection in the nucleus, differently from other
known Ru(III)complexes, able to accumulate in the cytoplasm but not in the nuclear region [153].
Notably, for these systems cationic DOTAP nanoaggregates proved to be more effective as Ru(III)-based
drugs carriers, showing faster uptake kinetics [77,79,100,106].
3.3. Sub-Cellular Accumulation of the Ru(III) Complexes
Ruthenium intracellular amount was determined by ICP-MS analysis performed on subcellular
fractions (culture medium, cellular pellet, cytosolic fraction, nuclear fraction and DNA sample) of
MCF-7 cells, after 24 h in vitro treatment with HoThyRu/DOTAP nanoaggregates [100]. AziRu was also
included as suitable control, demonstrating the vital importance of nanoformulations for an efficient
ruthenium cellular uptake and internalization [100]. In fact, after 24 h exposure, about 80% of the
administered AziRu was found in the culture medium, while 85% of the administered HoThyRu/DOTAP
liposomes amount was revealed at cellular level.
Furthermore, analysis of the isolated subcellular fractions indicated for the HoThyRu/DOTAP
formulations a broad ruthenium distribution among the intracellular compartments, above all in the
nucleus. Almost 50% of the ruthenium administered as liposomal nanosystem was found bound to
nuclear DNA vs. <10% of the metal from the naked AziRu detected in the nuclear fraction bound to
DNA [100].
3.4. Cell Morphological Changes Induced by in Vitro Treatment with Ru(III)-Containing Liposomes
To further support the relationship between cell viability and ruthenium-induced cytotoxicity,
subconfluent cultures of the selected cancer cell lines throughout the in vitro experiments were
also examined by phase-contrast light microscopy to monitor the dynamic morphological changes
occurring during cell death. Thus, confluent MCF-7, WiDr and C6 cancer cells were evaluated after
incubation with ToThyRu/POPC liposomes and MCF-7, WiDr and HeLa cells were examined after
in vitro treatments with ToThyCholRu/DOTAP formulations, as representative example of POPC and
DOTAP-based nanoaggregates, respectively.
In all cases, after 48 h in vitro treatments of the selected cancer cell lines, morphological
modifications of the cell monolayers were clearly evident [77,79], with distinctive hallmarks of
apoptosis (Figure 9a,b) [154]. Indeed, besides losing their normal morphology, apoptotic features—as
membrane blebs and cell shrinkage [154]—appeared in the treated cells together with a significant
increase of the number of rounded-up cells after exposure to the Ru(III)-containing liposomes [77,79].
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Figure 9. Representative photomicrographs by phase-contrast light microscopy showing the cellular
morphological changes and cytotoxic effects on cellular monolayers: untreated (left column in panels
a and b) or treated for 48 h with ToThyRu/POPC (a) or ToThyCholRu/DOTAP (b) formulations.
For ToThyRu/POPC nanosystems, MCF-7, WiDr and C6 cancer cell lines were examined (a); in turn,
for ToThyCholRu/DOTAP nanocarriers, MCF-7, WiDr and HeLa cancer cell lines were analysed (b).
Insets in (a) represent higher magnifications of injured cells following incubations with ToThyRu/POPC
liposomes. (c) MCF-7 and MDA-MB-231 breast cancer cells treated for 48 and 72 h with ruthenium IC50
concentrations of DoHuRu-containing liposomes. The inset in (c) represents higher magnifications at
0 (left panel) and 48 h (right panel) DoHuRu/DOTAP treated MCF-7 cells, showing the formation of
autophagic vacuoles detectable in cell cytoplasm. Figures are adapted from [77] (a), [79] (b) and [134] (c).
In the case of cytomorphological modifications induced by the treatment with the aminoacyl lipid
Ru(III) compound I hosted in DOTAP liposomes, not only malignant cells such as MCF-7, HeLa and C6
but also normal cell lines as 3T3-L1 (mouse embryo fibroblast) and HaCaT (human keratinocytes) were
analysed by phase-contrast light microscopy in the absence and presence of the drug. Notably, while
the cell distribution and cytomorphology were substantially unaffected on the healthy cells after 48 h
of in vitro treatment, under the same conditions the cell monolayers integrity was strongly perturbed,
with distinctive hallmarks of apoptotic cell death, such as membrane blebs, cell shrinkage, formation
of balloon-like structures and cell contraction [154], in the case of the cancer cells [110].
More recently, cellular cytomorphological changes induced by Ru(III)-containing liposome
administration were specifically investigated in two different breast adenocarcinoma cell lines,
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i.e., MCF-7 and MDA-MB-231 cells [146,147]. Indeed, in the presence of DoHuRu/POPC and
DoHuRu/DOTAP formulations at 48 or 72 h [134], photomicrographs indicated the characteristic cell
shrinkage as well as loss of cell-cell contacts, diagnostic of apoptosis (Figure 9c) [154].
Therefore, the overall morphological analysis outcomes provided strong evidence of an
apoptosis-inducing activity, in line with several in vitro studies supporting apoptotic events to
explain the anticancer properties of different ruthenium derivatives, both in their +2 and +3 oxidation
states [47,78,112,140,141,153,155–161]. However, also other different molecular pathways can be
involved in the cell death process [153]. In fact, in the case of MCF-7 cells treated with the
DoHuRu/DOTAP liposomes at IC50 conc., in addition to apoptotic hallmarks, also autophagic vacuoles
were clearly detectable, suggesting morphological changes associated with autophagy activation
(Figure 9c, inset) [134].
3.5. Insight into the Ru(III)-Containing Liposomes Mode of Action: Identification of Molecular Cell Death
Pathways
3.5.1. Pro-Apoptotic Effects in Breast Cancer Cells Evaluated by FACS Analysis
The observed changes both in the cell morphology and in the monolayers appearance
suggested that Ru(III)-containing liposomal formulations might exert their antiproliferative effects
in BCC by activation of specific cell death pathways, such as apoptosis and/or autophagy
mechanisms [77,79,110,134].
To investigate the apoptosis induction in MCF-7 and MDA-MB-231 cancer cells,
both DoHuRu-hosting POPC and DOTAP formulations were analysed by fluorescence-activated
cell sorting (FACS) analysis by using Annexin V-FITC (fluorescein isothiocyanate) along with the
propidium iodide (PI) dye, a very sensitive method to differentiate apoptotic (Annexin V-FITC positive,
PI negative) from necrotic (Annexin V-FITC positive, PI positive) cells [162].
Both DoHuRu-incorporating lipid formulations induced exceptional pro-apoptotic effects,
more marked for the DOTAP-based nanoaggregates, without observing significant increased necrosis
(Figure 10) [134]. In particular, for MCF-7 cells, after 48 h of treatment at IC50 conc. of the
tested formulations, 46% and 36% of total cell population, respectively, for DoHuRu/DOTAP and
DoHuRu/POPC formulations, were found in early stages of apoptosis (Annexin V-FITC positive and
PI negative). Additional 24 h treatment resulted in 82% and 37% of cell population, respectively,
for DoHuRu/DOTAP and DoHuRu/POPC formulations, in late apoptosis phase (positive for both
Annexin V-FITC binding and for PI uptake). Under the same conditions, similar trend and percentage
of cell population in the different apoptotic stages were found also for MDA-MB-231 cells, once again
with stronger pro-apoptotic effects for DOTAP- than POPC-based formulations (Figure 10) [134].
Indeed, these results further corroborated the increased in vitro efficacy—especially as a trend over
time—of the cationic DOTAP nanocarriers with respect to the zwitterionic POPC liposomes hosting
the same nucleolipidic Ru(III)-complex, likely due to different cellular uptake kinetics.
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is represented (bar graphs on the right of each panel). Viable cells are negative for both PI and FITC-
Annexin V binding; non-viable, necrotic cells are negative for FITC-Annexin V binding and positive 
for PI uptake; cells in early apoptosis are FITC-Annexin V positive and PI negative; cells in late 
apoptosis are positive for both FITC-Annexin V binding and PI uptake. Figures were adapted from 
[134]. 
3.5.2. DNA Fragmentation Assay 
It is generally accepted that apoptosis activation and subsequent DNA cleavage represent the 
main cytotoxic mode of action of metal-based antiproliferative drugs [4,141]. In addition to shrinkage 
and fragmentation of cells and nuclei, the apoptotic processes are also accompanied by a marked 
degradation of the chromosomal DNA in the nucleosomal area. Late events of apoptosis typically 
Figure 10. Induction of apoptosis in MCF-7 (a) and MDA-MB-231(b) breast cancer cells, evaluated by
FACS analysis (right on each panel), after cell labelling with propidium iodide (PI) and FITC-Annexin
V. Cells were both unlabelled and untreated (CTR −), labelled and not treated (CTR +), treated
with IC50 doses of DoHuRu-incorporating POPC or DOTAP liposomes for 48 and 72 h, as indicated.
The quantitative analysis of viable, non-viable (necrotic), early and late apoptotic cells after drug
exposure is represented (bar graphs on the right of each panel). Viable cells are negative for both PI
and FITC-Annexin V binding; non-viable, necrotic cells are negative for FITC-Annexin V binding and
positive for PI uptake; cells in early apoptosis are FITC-Annexin V positive and PI negative; cells in
late apoptosis are positive for both FITC-Annexin V binding and PI uptake. Figures were adapted
from [134].
3.5.2. DNA Fragmentation Assay
It is generally accepted that apoptosis activation and subsequent DNA cleavage represent the
main cytotoxic mode of ac ion of metal-ba ed antiproliferative drugs [4,141]. In addition to shrinkage
and fragmentation of cells and nuclei, the apop otic process s are also accompanied by a mar ed
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degradation of the chromosomal DNA in the nucleosomal area. Late events of apoptosis typically
lead to DNA fragmentation, resulting in a “ladder” formation easily detectable by agarose gel
electrophoresis [163]. Thus DNA cleavage extent in cultured cells is directly correlated with the amount
of apoptotic cells and this kind of investigation has been already explored for other Ru(III) complexes
after in vitro treatment of MCF-breast cancer cells [112,141,153].
To further sustain the evidence that Ru(III)-containing formulations were able to trigger apoptosis
in cancer cell lines, DNA degradation on genomic DNA samples obtained from treated cells was
also investigated. In particular, ToThyCholRu/DOTAP liposomes were evaluated for their DNA
fragmentation activity on MCF-7, WiDr and HeLa cancer cells (Figure 11a) [79]; while DoHuRu-hosting
lipid formulations were specifically evaluated on both MCF-7 and MDA-MB-231 breast cancer cells
(Figure 11b) [134].
Pharmaceuticals 2019, 12, x FOR PEER REVIEW 20 of 44 
 
lead to DNA fragmentation, resulting in a “ladder” formation easily detectable by agarose gel 
electrophoresis.[163] Thus DNA cleavage extent in cultured cells is directly correlated with the 
amount of apoptotic cells and this kind of investigation has been already explored for other Ru(III) 
complexes after in vitro treatment of MCF-breast cancer cells.[112,141,153] 
To further sustain the evidence that Ru(III)-containing formulations were able to trigger 
apoptosis in cancer cell lines, DNA degradation on geno ic DNA samples obtained from treated 
cells was also investigated. In particular, ToThyCholRu/DOTAP liposomes were evaluated for their 
DNA fragmentation activity on MCF-7, WiDr and HeLa cancer cells (Figure 11a);[79] while DoHuRu-
hosting lipid for ulations were specifically evaluated on both MCF-7 and MDA-MB-231 breast 
cancer cells (Figure 11b).[134] 
In all cases, the  extracted from cells following 48 h of incubation with IC50 doses of Ru(III)-
containing formulations strongly indicated fragmentation, acco panied by typical internucleosomal 
DNA laddering. The DNA cleavage extent was very close to that induced by cisplatin, used as 
positive control,[163] while no relevant DNA fragmentation was found in untreated cancer cells 
(Figure 11).[79,134] 
 
Figure 11. 1.5% agarose gels representing the DNA fragmentation assay on MCF-7, WiDr and HeLa 
cells, treated or not (Ctrl) for 48 h with IC50 doses of ToThyCholRu–DOTAP liposomes (indicated as 
Ru) (a) and MCF-7 and MDA-MB-321 cells treated or not (C) with IC50 concentrations of 
DoHuRu/POPC (RuPOPC) and DoHuRu/DOTAP (RuDOTAP) for 48 h (b). In both experiments, the 
selected cell lines were also treated with IC50 conc. of cisplatin (cDDP) used as a control. Lane M 
corresponds to the molecular weight markers. Figures are adapted from [79] (a) and [134] (b). 
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cancer cells was not typical. This was explained considering that this cell line is particularly resistant 
to chemotherapeutics due to deletion in the CASP-3 gene, leading to an inherited caspase-3 deficiency 
expression.[164] Caspase-3 proteins are commonly activated by different death signals and are 
therefore responsible of cleavage of important cellular proteins and ultimately of apoptotic DNA 
damage.[165] In this case, MCF-7 cells undergo cell death triggered by apoptotic stimuli in the 
absence of canonical DNA fragmentation and thus activating mechanisms independent of caspase-3 
but associated with different effector caspases, such as caspase-6 or -7.[166,167] 
3.5.3. Apoptotic-Related Protein Expression in Breast Cancer Cells 
In addition to the fundamental role of caspase-3 in the DNA damage induction, all the 
intracellular caspases and BCL-2 (B-cell lymphoma-2) family proteins represent key elements for 
cancer response to chemotherapeutic intervention due to their involvement in the fine regulation of 
the apoptotic cell death machinery.[168] In particular, the family of BCL-2 contains protein factors 
playing a critical role in controlling dynamic cellular processes, decision-making between life and 
commitment to the mitochondrial apoptosis (intrinsic apoptotic pathway). BCL-2 was discovered as 
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Figure 11. 1.5% agarose gels representing the DNA fragmentation assay on MCF-7, WiDr and HeLa
cells, treated or not (Ctrl) for 48 h with IC50 doses of ToThyCholRu–DOTAP liposomes (indicated as Ru)
(a) and MCF-7 and MDA-MB-321 cells treated or not (C) with IC50 concentrations of DoHuRu/POPC
(RuPOPC) and DoHuRu/DOTAP (RuDOTAP) for 48 h (b). In both experiments, the selected cell lines
were also treated with IC50 conc. of cisplatin (cDDP) used as a control. Lane M corresponds to the
molecular weight markers. Figures are adapted from [79] (a) and [134] (b).
In all cases, the DNA extracted from cells following 48 h of incubation with IC50 doses
of Ru(III)-containing formulations strongly indicated fragmentation, accompanied by typical
internucleosomal DNA laddering. The DNA cleavage extent was very close to that induced by
cisplatin, used as positive control [163], while no relevant DNA fragmentation was found in untreated
cancer cells (Figure 11) [79,134].
However, in all the tested formulations, the nuclear fragmentation pattern observed for MCF-7
cancer cells was not typical. This was explained considering that this cell line is particularly resistant
to chemotherapeutics due to deletion in the CASP-3 gene, leading to an inherited caspase-3 deficiency
expression [164]. Caspase-3 proteins are commonly activated by different death signals and are
therefore responsible of cleavage of important cellular proteins and ultimately of apoptotic DNA
damage [165]. In this case, MCF-7 cells undergo cell death triggered by apoptotic stimuli in the
absence of can ical DNA fragmentation and thus activating mechanisms independent of caspase-3
bu ssociated with different effector caspases, such s caspase-6 or -7 [166,167].
3.5.3. Apoptotic-Related Protein Expression in Breast Cancer Cells
In addition to the fundamental role of caspase-3 in the DNA damage induction, all the intracellular
caspases and BCL-2 (B-cell lymphoma-2) family proteins represent key elements for cancer response to
chemotherapeutic intervention due to their involvement in the fine regulation of the apoptotic cell
death machinery [168]. In particular, the family of BCL-2 contains protein factors playing a critical
role in controlling dynamic cellular processes, decision-making between life and commitment to the
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mitochondrial apoptosis (intrinsic apoptotic pathway). BCL-2 was discovered as a new oncoprotein in
acute lymphoblastic leukaemia, protecting cells from programmed cell death as apoptosis inhibitor and
promoting cellular survival by inhibition of Bax and Bid action on mitochondria [169]. Many BCL-2
proteins with anti-apoptotic activities have been discovered, including B-cell lymphoma-extra-large
(BCL-xL), BCL-2-like protein 2 (BCL-w), BCL-2-like protein 10 (BCL-B), myeloid cell leukemia 1
(MCL-1) and BCL-2 related gene A1 (A1). Conversely, the pro-apoptotic effectors of the BCL-2
family members, such as Bax and Bid, can commit a cell to its programmed death by promoting
the permeabilization of its mitochondrial outer membrane (MOM) and the activation of the caspase
cascade [170]. As a consequence, cytc and other intermembrane space (IMS) mitochondrial proteins are
released into the cytosol, playing a central role in the apoptosome formation that subsequently activates
caspase 9. In turn, caspase 9 activates effector caspases 3, 6 and 7, cleaving vital cellular proteins and
ultimately ensuring cellular demolition (Figure 12, right). The intrinsic pathway is typically activated
by intracellular stress signals [165,171]. Several clinical studies demonstrated that the overexpression
of the antiapoptotic BCL-2 protein is a negative prognostic marker in various tumours [172]; while high
Bax expression was associated with a better response to chemotherapy in many cancers forms [173,174].
Pharmaceuticals 2019, 12, x FOR PEER REVIEW 21 of 44 
 
as apoptosis inhibitor and promoting cellular survival by inhibition of Bax and Bid action on 
mitochondria.[169] Many BCL-2 proteins with anti-apoptotic activities have been discovered, 
including B-cell lymphoma-extra-large (BCL-xL), BCL-2-like protein 2 (BCL-w), BCL-2-like protein 
10 (BCL-B), myeloid cell leukemia 1 (MCL-1) and BCL-2 related gene A1 (A1). Conversely, the pro-
apoptotic effectors of the BCL-2 family members, such as Bax and Bid, can commit a cell to its 
programmed death by promoting the ermeabiliz tion of its mitochondrial outer membrane (MOM) 
nd the activation of the caspase cascade.[170] As a consequenc , cytc and other intermembrane space 
(IMS) mitochondrial proteins are released into the cytosol, playing a central role in the apoptosome 
formation that subsequen ly at  caspase 9. In turn, caspase 9 activates effector caspases 3, 6 and 
7, cleaving vital cellular proteins and ultimately ensuring cellular demolition (Figure 12, right). The 
intrinsic pathway is typically activated by intracellular stress signals.[165,171] Several clinical studies 
de onstrated that the overe pression of the antiapoptotic BCL-2 protein is a negative gnostic 
mark  in various tumours;[172] while high Bax expression was associa ed wi h  better response to 
hemotherapy in many cancers forms.[173,174] 
Conversely, the extrinsic pathway is generally activated by extr cellular ligands able to bind to 
death receptors on the cell surface, l ading t  the formation of the death-inducing signalling complex 
(DISC). Formatio  of DISC—typically trig ered by members of he death receptor superfamily, such 
as CD95 and tumour necrosis factor recepto —induces in turn caspase-8 activation and thereby the 
downstre m caspase cascade (Figure 12, left).[175] Thus, specific activation of some caspases or BCL-
2 factors are suggestive of he induction of distinctive apopt tic pathways. [171,175] 
 
Figure 12. Schematic representation of the intrinsic (or mitochondrial) and the extrinsic (or death 
receptor) apoptotic pathways. 
Thus, Western blot analysis was used to investigate protein expression profile in treated MCF-7 
and MDA-MB-231 cells after exposure to IC50 of DoHuRu/POPC and DoHuRu/DOTAP formulations 
at 48 and 72 h.[134] In both the investigated BCC lines, a considerable increase in caspase-9 activity 
Figure 12. Schematic representation of the intrinsic (or mitochondrial) and the extrinsic (or death
receptor) apoptotic pathways.
Conversely, the extrinsic pathway is generally activated by extracellular ligands able to bind to
death receptors on the cell surface, leading to the formation of the death-inducing signalling complex
(DISC). Formation of DISC—typically triggered by members of the death receptor superfamily, such as
CD95 and tumour necrosis factor receptor—induces in turn caspase-8 activation and thereby the
downstream caspase cascade (Figure 12, left) [175]. Thus, specific activation of some caspases or BCL-2
factors are suggestive of the induction of distinctive apoptotic pathways [171,175].
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Thus, Western blot analysis was used to investigate protein expression profile in treated MCF-7
and MDA-MB-231 cells after exposure to IC50 of DoHuRu/POPC and DoHuRu/DOTAP formulations
at 48 and 72 h [134]. In both the investigated BCC lines, a considerable increase in caspase-9 activity
with respect to untreated cells was detected—resulting in the production of active p35 and p37
subunits, known to amplify the apoptotic response—along with a simultaneous Bax up-regulation
and BCL-2 down-regulation (Figure 13) [134]. These biological responses were time-dependent and
more evident after treatment in vitro with the cationic DoHuRu/DOTAP liposome [134]. The activation
of pro-caspase-9, together with the changed Bax/BCL-2 ratio, suggested a Ru-dependent activation
of the apoptotic intrinsic pathway, probably as a result of interactions with putative mitochondrial
targets, maybe via selective ROS generation and accumulation, as already found for other Ru(II) and
Ru(III)-based drugs [176].
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Figure 13. Western blot analysis showing the effects of IC50 doses of DoHuRu/POPC and
DoHuRu/DOTAP following 48 and 72 h of incubation in MCF-7 (a) and MDA-MB-231 (b) cells
on caspases-3, -8 and -9 expression and activation, and on Bax and BCL-2 expression. Bands resulting
after chemoluminescence from tr ells wer extracted, quantified by densi ometric an lysis and
then plotted (graphs on the right anel): solid an dotted lines for Bax and BCL-2 expression
proteins, resp ctively, and bar graphs (caspases-3, -8 and -9) reported as percentage of control in relation
to the used Ru-containing nanoaggregates. Figures are adapted from [134].
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Notably, while no activation of caspase-8 appeared even after 72 h of exposure to the zwitterionic
POPC-based nanosystems, the cationic DoHuRu/DOTAP nanoaggregates seemed to promote full
length pro-caspase-8 cleavage, as evidenced by the formation of p10 and p18 fragments (Figure 13),
fundamental active elements in the extrinsic death pathway [134].
Hence, DoHuRu/DOTAP formulations were able to concurrently trigger the induction of the
two major apoptotic processes. Moreover, the activation of both apoptotic pathways (the intrinsic
and the extrinsic one) seems to occur in a cell-specific manner, being evident only in MDA-MB-231
cells (Figure 13b). Possibly, the net positive surface charge of DOTAP-based nanoaggregates allows
interacting in a peculiar manner with the cell membrane external bilayer, stimulating specific surface
receptors involved in the activation of the death receptor pathway. However, these findings are
not unprecedented since the activation of extrinsic apoptosis pathways [177], as well as the ability
of some Ru(II) and Ru(III) complexes to simultaneously activate intrinsic and extrinsic apoptosis
pathways, [178] have been demonstrated for other anticancer chemotherapeutics.
3.5.4. Autophagy Activation in Breast Cancer Cells
In addition to apoptotic pathway, cellular suicide may also occur via non-apoptotic forms
of programmed death such as autophagy [179,180]. Autophagic activity—generally low under
basal conditions—can be specifically up-regulated in the presence of several physiological and
non-physiological stimuli, including in vitro pharmacological treatments. [181,182] As in the case of
apoptosis, autophagy play a crucial role in early stages of carcinogenesis, in cellular proliferation and
survival [182–188]. Excessive autophagy is associated with cell death, as well as with other death
pathways depending on cell types—an aspect to be taken into account as ruthenotherapy additionally
activates apoptosis [189,190].
Since the activation of a pro-apoptotic response by chemotherapy can be affected by several
factors, including cancer phenotypes and specific gene mutations, ultimately affecting the therapy
success, the induction of alternative cell death pathway, alone or coupled to the apoptotic one [191],
could represent an attractive goal in future anticancer intervention, especially in metastatic breast
cancer cells [192,193]. The recent discovery of crosstalk connection among different cell death effectors
and signalling pathways [194–196] will in fact offer novel effective therapeutic opportunities for
targeted cancer therapies [197].
Notably, some Ru(II) complexes were found to be able to activate autophagy in cancer cells,
though occasionally in antagonism to mitochondrial-mediated apoptosis [198,199]. A late step
of the autophagic cell death consists of the autolysosomes formation, which is dependent on
the coordinated activity of autophagy-related (Atg) proteins [186] involved in the maintenance
of the cellular homeostasis [183,184,186,187,200]. Therefore, the formation of autophagic vacuoles
visualized via monodansylcadaverine (MDC), a selective autofluorescent marker for autolysosomes
detection [201]—in BCC treated with either DoHuRu/POPC or DoHuRu/DOTAP—was verified to
evaluate the ability of Ru(III)-based compounds to induce also autophagy [134].
FACS analysis was used for the quantitative determination of MDC staining in MCF-7 and
MDA-MB-231 cells exposed for 48 and 72 h to ruthenium IC50 doses (Figure 14) [134]. While the
treatment with DoHuRu/POPC did not reveal significant autolysosome formation, the cellular exposure
to DoHuRu/DOTAP liposomes indicated a significant formation of the MDC-labelled vacuoles already
after 48 h (Figure 14). These results suggest the capability of the cationic nanoaggregates to activate
autophagy in the presence of apoptosis [134].
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The ability of DoHuRu-hosting cationic liposomes to induce autophagy could be associated with
the ruthenium-induced down-regulation of the prosurvival protein BCL-2: indeed, interferences in
the interaction between Beclin-1 and BCL-2 family proteins, by which Beclin-1 is inhibited in normal
conditions, stimulate autophagy [202].
To get further insight into the ability of the Ru(III)-containing formulations to induce autophagic
cell death in cancer cells, MCF-7 breast cells treated with HoThyRu/DOTAP liposomes were processed
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with a fluorescent autophagic detection kit able to measure autophagic vacuoles and to monitor
the autophagic flux in live cells. DAPI was used to stain nuclei and FITC to visualize autophagic
vesicles, such as autophagosomes and autophagolysosomes, and then the percentage of positive cells
to autophagy was assessed [100]. In this way HoThyRu/DOTAP liposomes were demonstrated to
strongly promote the formation of cytosolic autophagic vacuoles [100], reaching after 72 h similar
effects to those induced by rapamycin, used as positive control being one of the most potent autophagy
inducers [203].
3.5.5. Autophagy-Related Proteins Expression in Breast Cancer Cells
The formation of autophagosomes represents the last step of autophagy process in which at least
16 proteins are involved: among these, only the LC3 protein strongly associates with the membrane of
autophagosomes. This protein exists in two different forms: LC3-I and LC3-II, found respectively in the
cytoplasm and as membrane-bound form. LC3-phosphatidylethanolamine conjugate (LC3-II) differs
from LC3-I being covalently linked to lipid moieties [204] starting from LC3-I to initiate the formation
of the autophagosome vacuoles [182,184]. The autophagosomal marker LC3-II reflects autophagic
activity, so that LC3 monitoring by both immunoblotting and immunofluorescence has become a
consistent method for autophagy detection [205]. In addition, the Beclin-1 activity is very important
in autophagy cell death pathway: this protein is a component of the phosphatidylinositol-3-kinase
(PI3K) complex, which is required for autophagosome formation, and the expression of Beclin-1 was
found decreased in malignant breast epithelial cells [206–208]. Recent data also suggested a lack
of autophagic pathways following Beclin-1 depletion which can be induced by different conditions,
including chemotherapeutic interventions [209]. As demonstrated by immunoblot analysis (Figure 15),
protein samples extracted from MCF-7 and MDA-MB-231 cells, following in vitro treatments with
HoThyRu/DOTAP liposomes for 48 and 72 h, showed a relevant increase in both LC3 proteins, and
mainly in the LC3-II form [100]. In parallel, Bax was significantly increased and BCL-2 decreased,
and no relevant change between untreated and treated cells was found in Beclin-1 protein content
(Figure 15).
As survival factor, BCL-2 down-regulation proved to promote the activation of autophagic cell
death [210–212]. In addition, the maintenance of basal amounts of Beclin-1 after exposure to cationic
Ru-based nanosystems could be decisive in regulating the induction of autophagy. Indeed, fluorescent
bioimaging of MCF-7 cells treated with HoThyRu-containing DOTAP formulations and stained for
LC3 indicated an intense protein immunoreactivity, likely localized into autophagic vacuoles in the
cytoplasm [100].
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3.6. In Vivo Anticancer Efficacy of Ru(III)-Containing Liposomes in Mice BCC Xenografts
In a prelimi ary investigation focused on in vivo response to HoThyRu/DOTAP formulation,
athymic nude mice bearing human BCC xenografts were subcutaneously inoculated into the right flank
with MCF-7 cells. Two weeks after the tumour growth, intraperitoneal injection of HoThyRu/DOTAP
na oaggregates was carried out o ce a week for four weeks. At the end of the schedule, the mice
were sacrificed and the tumours collected (Figure 16) [100]. Subsequent analysis showed that the
administration of HoThyRu/DOTAP formulation significantly inhibited breast cancer cell proliferation
in mice, with a relevant reduction in both the weight and volume of tumour lesions with respect to the
control group (Figure 16a–c). Notably, mice survival was 100%, and body weights were not affected by
the ruthenium treatments (Figure 16d,e). Moreover, no evident toxicity was observed on the treated
mice, suggesting a very good in vivo tolerance of the HoThyRu-hosting DOTAP nanosystems [100].
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4. Improved Ru(III)-Containing Nanosystems: Introduction of Targeting and/or Diagnostic
Agents for Theranostic Applications
Starting from the promising in vitro bioactivity of Ru(III)-containing POPC- and DOTAP-based
liposomes, able to selectively and significantly reduce cancer cell survival, further improvements of
these systems were recently proposed. In particular, two alternative approaches were reported based
on varying the platform used to deliver the nucleolipid-based Ru(III)-complexes.
In a first approach, niosome vesicles were used to replace liposomes.
In detail, vesicles prepared from non-ionic surfactants [213,214], currently known as niosomes or
NSVs (non-ionic surfactant vesicles), gained increasing attention as drug delivery systems, providing
a cheaper and more stable alternative to phospholipids used in liposome preparation [215,216].
Niosomes are self-assembled vesicles made up of single chain non-ionic surfactants combined with
cholesterol or other lipids [217,218]. Charged molecules can be also added as ingredients to better
stabilize the obtained formulations and prevent their aggregation over time [214,215,218,219].
Owing to their vesicle structure, niosomes are able to incorporate both hydrophilic and
hydrophobic drugs, just like liposomes do [216,218,220,221]. The drug is entrapped in a membrane
resulting from the self-assembly of the surfactant + lipid molecules, generally organized in stable
bilayers [222]. Niosomes can protect the loaded drugs from premature degradation or possible
inactivation overcoming some major biopharmaceutical problems such as insolubility, side effects,
and poor chemical stability of drugs [223,224]. Moreover, the high chemical stability of surfactants,
compared with phospholipids, makes niosome purification, handling and storage much easier than
those of conventional liposomes [225,226].
In our approach, the use of niosomal formulations allowed the introduction in the lipid formulation,
besides the Ru(III)-based complexes, also of an active targeting agent, i.e., the oligodeoxyribonucleotide
AS1411 [109]. This G-rich 26-mer, carrying the sequence 5
′
GGTGGTGGTGGTTGTGGTGGTGGTGG3
′
,
entered in Phase II anticancer clinical trials, selectively targets nucleolin, a multifunctional protein
involved in cell survival, growth and proliferation, overexpressed on the outer membrane of cancer
cells (for a recent review covering the state-of-the-art knowledge on AS1411, see P. J. Bates et al. [227]).
Recently, AS1411 has been largely employed as a selective nucleolin-targeting agent, successfully
combined with chemotherapeutic agents (such as paclitaxel [228–231], docetaxel [232–234],
doxorubicin [235–244], and epirubicin) [245] onto suitable nanosystems in the context of specific
recognition of cancer cells and tumour-selective delivery of therapeutic or imaging agents for cancer
treatment [227].
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In the proposed niosome formulations, AS1411 was for the first time associated with a Ru(III)-based
chemotherapeutic drug to improve its selective delivery via specific recognition of cancer cells [109].
In a second approach, superparamagnetic iron oxide NPs (SPIONs) with a core/double shell
architecture were exploited as platform for Ru incorporation, proving to be effective contrast agents
for in vivo Magnetic Resonance Imaging (MRI) investigations and thus potential tools in theranostic
nanomedicine, intended to provide simultaneous diagnosis and treatment of a disease, with early
detection, easy monitoring, targeted therapy and minimal toxicity [246,247].
4.1. Niosome-Based Systems Containing Nucleolipid-Based Ru(III) Complexes
With the aim of exploring niosome vesicles as versatile scaffolds for effective loading of
multiple anticancer drugs to be used in combination therapies, Riccardi et al. [109] devised a novel
formulation—mixing a cationic lipid, i.e., [2,3-di(tetradecyloxy)propan-1-aminium chloride] and the
non-ionic surfactant polysorbate 80 in 3:1 molar ratio—as optimized vesicles with respect to previously
described ones (Figure 17) [248,249]. Then, these niosomal formulations were decorated with the
anticancer drug HoThyRu—hitherto one of the most effective ones among the nucleolipidic-based
Ru(III) complexes investigated—as well as with the G-quadruplex-forming aptamer AS1411, to ensure
highly specific recognition towards cancer cells (Figure 17) [109].
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polysorbate 80, also containing the nucleolipid-based Ru(III) complex HoThyRu along with AS1411.
On the right, the tr ti / ff cts bar graphs obtained after in vitro treatment on HeLa can er lls
were also reported as representative examples. Figures were adapted from [109].
The morphology, av rage size, zeta potential, electrophoretic mobility and stability over time of
the functionalized niosomes were analysed using different biophysical techniques.
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In particular, both unfunctionalized and functionalized niosomes gave monodisperse vesicle-like
aggregates, with typical size of ca. 100 nm, stable upon storage for one month, also able to
fully incorporate both the nucleolipid Ru(III) complex HoThyRu and the oligonucleotide AS1411.
The functionalization was driven by electrostatic interactions, in the case of the negatively-charged
oligonucleotide, and by a combination of hydrophobic and electrostatic interactions for HoThyRu
encapsulation [109].
Then, the antiproliferative activity of the niosome formulations was evaluated using the MTT
assay on a selected panel of human cells including a human cervix adenocarcinoma (HeLa) and two
colorectal cancer cell lines (HTB-38, HCC2998), as well as a non tumoural embriogenic human cell
line (HEK293T). HeLa cells were selected as a relatively drug-sensitive cell line with high nucleolin
content, already proved to be responsive to niosome formulations [249] as well as to AS1411 [227].
In contrast, HTB-38 and HCC2998 colorectal cancer cell lines were chosen being highly resistant
even to very effective chemotherapeutic agents such as 5-fluorouracil and camptothecin [250,251].
Finally, the embryogenic cell line HEK293T was included as healthy cell line, already investigated to
verify the absence of toxicity of niosome formulations [252].
Niosome formulations containing both AS1411 and HoThyRu showed increased bioactivity
compared to those carrying only HoThyRu, proving the ability of the nucleolin-targeting aptamer
to markedly enhance the bioactivity of the Ru(III)-containing niosomes (in Figure 17, on the right,
the concentration/effect curves obtained on HeLa cells were reported as a representative example).
The obtained response was however cell-dependent, with HeLa cells more sensitive to this drug
treatment than colorectal cancer cells [109]. The observed lower antiproliferative activity on both
HCC2998 and HTB-38 colorectal cancer cell lines can be explained considering their generally poor
sensitivity to drug treatments and low expression of nucleolin. Taken together, these results proved
niosome formulations as very interesting nanocarriers to transport in cells anticancer drugs and the
efficacy of AS1411 as targeting agent also in niosomal systems [109].
4.2. Nanoparticle-Based Systems Containing Nucleolipid-Based Ru(III) Complexes
Stable phosphocholine-functionalized SPIONs (18LPC/SPIONs) were recently prepared through
thermal decomposition method exploiting hydrophobic interactions between a suitable phosphocholine,
i.e., 1-octadecyl- 2-hydroxy-sn-glycero-3-phosphocholine (18LPC), and an inner amphiphilic layer
(composed by oleic acid and oleylamine), covering the surface of the NPs [108,253,254].
18LPC-SPIONs were further decorated with the nucleolipid-based Ru(III)-complex ToThyCholRu
(18LPC-ToThyCholRu/SPIONs) [108], lodged in the external coating layer of the nanoparticle surface
through reversible hydrophobic interactions (Figure 18a). Then, all the prepared SPION systems were
characterized by DLS, TEM, small-angle X-ray scattering (SAXS) and wide-angle X-ray scattering
(WAXS) measurements.
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The successive evaluation of the bioactivity of the ToThyCholRu-functionalized SPIONs on selected
human cancer and non-cancer cells (MCF-7 breast adenocarcinoma, human HaCaT keratinocytes,
murine 3T3L-1 fibroblasts, human Calu-6 and A549 lung carcinoma cell lines) confirmed the potential
of this system as an effective theranostic device (Figure 18b) [108]. Indeed, 18LPC/SPIONs were devoid
of significant biological effects, even at 100 µg/mL iron concentration on both cancer and healthy cell
lines, (Figure 18b) while the incorporation of the amphiphilic ruthenium complex ToThyCholRu in the
SPION surface induced a significantly enhanced bioactivity, providing significant cytotoxic effects in
cancer cells without affecting healthy cells (Figure 18b) [108]. Notably, when inserted in the SPION
nanosystems, ToThyCholRu was also very effective in inhibiting MCF-7 proliferation, with ca. four-fold
higher cytotoxicity compared to the same Ru(III) complex loaded in POPC; conversely the inhibition
efficiency was similar to that observed after loading in cationic DOTAP-based nanoaggregates (see
data reported in Table 1).
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In analogy to previous investigations (Section 3.4), subconfluent breast MCF-7 culture cells
were also examined by phase-contrast light microscopy indicating that the in vitro exposure to
18LPC/SPIONs did not alter cell morphology, whereas after Ru-loaded NPs administration, significant
cytological changes of the cell monolayers clearly appeared (Figure 18c) [108].
Once assessed for their biocompatibility, 18LPC/SPIONs were also injected in the tail vein
of a healthy rat, chosen as a small animal model to evaluate their in vivo pharmacokinetics and
applicability as negative contrast agents for MRI analyses (Figure 18d). This effect is typically evaluated
with the transverse proton relaxation time (T2) reduction or transverse proton relaxation rate (R2)
increase [255,256].
Ten minutes after injection, a notable T2 relaxation time decrease was recorded in the liver of the
animal, consistently with the nanoparticle capture by the reticuloendothelial hepatic tissue (Kupffer
cells) [257], without significant variation in other organs (e.g., kidneys and heart). Then, according to
the progressive accumulation of the 18LPC/SPIONs in the tissue for excretion, R2 reached a maximum
value 60 min after injection [108].
Thus, 18LPC/SPIONs demonstrated to favour long circulation times with a measurable reduction
in the MR signals in the rat liver, indicating a very promising potential for use as MRI negative contrast
agents [108].
More recently, as additional ingredients for the SPIONs surface decoration, suitable lipophilic
AS1411 conjugates were also studied [258] in order to evaluate in future studies the ability of AS1411
to enhance the Ru(III)-based compounds uptake and, thus, their overall anticancer activity also when
incorporated onto SPIONs.
5. Conclusions
Cancer is one of the leading causes of death in the world, representing a key topic in scientific
research. Cancer cells are able to accumulate multiple mutations allowing their uncontrollable
growing, invasiveness, and eventually spreading to other parts of the body causing tumour metastasis
formation. In addition, malignant cells typically exhibit aberrations in the physiological signalling
pathways regulating various cellular processes, such as cell growth and division, as well as cell-to-cell
communication. Therefore, the genetic and phenotypic heterogeneities of tumours form, making
cancer a very difficult disease to treat.
Stimulated by the success of cisplatin, intense efforts have been devoted to the development of
alternative transition metal-based anti-tumour compounds. Pioneering studies in this field led to
promising lead Ru(III)-complexes, such as NAMI-A, KP-1019 and NKP-1339, which entered clinical
trials, even though none of these have been approved yet for human use.
The difficulty of progressing lead compounds from animal studies to human clinical trials and/or
effective clinical use highlights the complications involved in overcoming the pharmacokinetic and
pharmacodynamic barriers in living animals. Metal compounds with proved selective anti-tumour
in vitro activity are presumably able to reach the target tumour xenograft without causing adverse
effects to the health of the animal. Nevertheless, this is not always verified since a compound active
in vitro against cancer cell lines can fail under in vivo testing for several reasons. For example,
the lipophilicity of complexes is determinant for effective cellular uptake. Secondly, the compound
may be too unstable in human plasma or may be cleared too quickly by the liver. Alternatively, a
compound may be too toxic to a particular organ, even though it may not show cytotoxicity in vitro
against normal cell lines.
In this context, the encapsulation of Ru(III) complexes into nanostructures is an increasing research
area, particularly useful to address the uptake and stability issues of these anticancer agents; therefore,
some ground-breaking advances are expected in the near future. Nanoformulations can be used to
enhance the efficacy of Ru complexes in cancer treatment by targeted delivery of drugs into cancer
cells and reduce their adverse effects and systemic toxicity by optimization of their pharmacokinetic
properties. Notably, examples have been here discussed showing the ability of Ru(III)-functionalized
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liposomes to activate multiple cell death pathways, which represents a very interesting perspective in
order to develop new intervention strategies in TNBC with limited chemotherapeutic options.
Although nanostructured materials functionalized with Ru complexes (micelles, liposomes,
niosomes and iron oxide nanoparticles) have shown great potential in the treatment of cancer, there are
still many challenges in translating basic research into clinical applications.
To reach these challenging goals, understanding the pharmacokinetic and pharmacodynamic
parameters of a drug is essential for the design of dosage administration regimens, as well as to help
reducing toxicity effects and enhancing target drug delivery. A more in-depth understanding of the
mechanism of action of the hit/lead compounds could also potentially help to improve the potency
and selectivity of the candidate drugs through rational design of optimized drugs.
Finally, significant efforts must be invested in developing extensive in vivo screenings in
models that mimic human pathophysiology in order to achieve higher predictability for successful
Ru(III)-drug development.
Overall, research on the encapsulation of Ru(III) complexes will undoubtedly continue to develop
and, owing to the high structural variety of nanosystems and Ru derivatives, new delivery platforms
will certainly be realized in the near future for anticancer therapies.
Based on the continuous efforts that worldwide researchers have invested in this field, our feeling
is that it is only a matter of time before new metal complexes with superior efficacy and low toxicity
will be approved as anticancer therapeutics, finally replacing longstanding metal-based anticancer
drugs as cisplatin and its derivatives.
In this context, the next years will witness progress in elucidating real targets and mechanisms
of action that will provide solid scientific basis for extensive preclinical development of selected
Ru(III)-containing formulations.
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